dividendsplus Sunday, 08/06/17 01:13:00 PM Re: fga post# 1181 Post # of 1221 True, cannot know. But here's the rub, the last news related to CC-31244 which gad a promising study and which seems to be a good candidate for more clinical trials. Last quarter they announced that they were looking for a partner for this on this compound and of course we haven't heard anything. Why? If this is Schinazi, the founder of Pharmasset who sold to Gilead gor $11bn, why is it that nobody is interested in partnering here? (at least as far as we know) The only news is the appointment of the interim CFO as a permanent CFO and we see that Schinazi exercised some optioms to buy stock at just over 4 cents per share. The stock continues to be in the doldrums with market excitement over the participants seemingly non existent. Bit disconcerting. At least the 10Q is coming.